373 related articles for article (PubMed ID: 37261523)
1. To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations.
Cai R; Zhu H; Liu Y; Sha H; Peng W; Yin R; Zhou G; Fang Y
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10027-10040. PubMed ID: 37261523
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC.
Alessi JV; Elkrief A; Ricciuti B; Wang X; Cortellini A; Vaz VR; Lamberti G; Frias RL; Venkatraman D; Fulgenzi CAM; Pecci F; Recondo G; Di Federico A; Barrichello A; Park H; Nishino M; Hambelton GM; Egger JV; Ladanyi M; Digumarthy S; Johnson BE; Christiani DC; Lin X; Gainor JF; Lin JJ; Pinato DJ; Schoenfeld AJ; Awad MM
J Thorac Oncol; 2023 Jun; 18(6):731-743. PubMed ID: 36775193
[TBL] [Abstract][Full Text] [Related]
3. Genomic landscape of non-small-cell lung cancer with methylthioadenosine phosphorylase (MTAP) deficiency.
Ashok Kumar P; Graziano SL; Danziger N; Pavlick D; Severson EA; Ramkissoon SH; Huang RSP; Decker B; Ross JS
Cancer Med; 2023 Jan; 12(2):1157-1166. PubMed ID: 35747993
[TBL] [Abstract][Full Text] [Related]
4. Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC.
Mok TSK; Lopes G; Cho BC; Kowalski DM; Kasahara K; Wu YL; de Castro G; Turna HZ; Cristescu R; Aurora-Garg D; Loboda A; Lunceford J; Kobie J; Ayers M; Pietanza MC; Piperdi B; Herbst RS
Ann Oncol; 2023 Apr; 34(4):377-388. PubMed ID: 36709038
[TBL] [Abstract][Full Text] [Related]
5. [The efficacy and prognostic factors of immunotherapy in advanced non-small cell lung cancer patients with different driver gene mutations].
Ma SX; Ma N; Han J; He Z; Wang L; Wang Q
Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(13):922-929. PubMed ID: 35385963
[No Abstract] [Full Text] [Related]
6. STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP).
Cordeiro de Lima VC; Corassa M; Saldanha E; Freitas H; Arrieta O; Raez L; Samtani S; Ramos M; Rojas C; Burotto M; Chamorro DF; Recondo G; Ruiz-Patiño A; Más L; Zatarain-Barrón L; Mejía S; Nicolas Minata J; Martín C; Bautista Blaquier J; Motta Guerrero R; Aliaga-Macha C; Carracedo C; Ordóñez-Reyes C; Garcia-Robledo JE; Corrales L; Sotelo C; Ricaurte L; Santoyo N; Cuello M; Jaller E; Rodríguez J; Archila P; Bermudez M; Gamez T; Russo A; Viola L; Malapelle U; de Miguel Perez D; Rolfo C; Rosell R; Cardona AF
Lung Cancer; 2022 Aug; 170():114-121. PubMed ID: 35753125
[TBL] [Abstract][Full Text] [Related]
7. Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial.
Cortellini A; Ricciuti B; Borghaei H; Naqash AR; D'Alessio A; Fulgenzi CAM; Addeo A; Banna GL; Pinato DJ
Cancer; 2022 Aug; 128(16):3067-3079. PubMed ID: 35727053
[TBL] [Abstract][Full Text] [Related]
8. [A Real-world Study on the Assessment of Pathological Characteristics and Targeted Therapeutic Effect of Non-small Cell Lung Cancer Patients with Positive Driving Genes and High PD-L1 Expression].
Zhang H; Yang X; Li K; Wang J; Lv J; Li X; Zhang X; Qin N; Zhang Q; Wu Y; Ma L; Gai F; Hu Y; Zhang S
Zhongguo Fei Ai Za Zhi; 2021 Feb; 24(2):78-87. PubMed ID: 33478196
[TBL] [Abstract][Full Text] [Related]
9. STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?
Di Federico A; De Giglio A; Parisi C; Gelsomino F
Eur J Cancer; 2021 Nov; 157():108-113. PubMed ID: 34500370
[TBL] [Abstract][Full Text] [Related]
10. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract][Full Text] [Related]
11. NFE2L2/KEAP1 Mutations Correlate with Higher Tumor Mutational Burden Value/PD-L1 Expression and Potentiate Improved Clinical Outcome with Immunotherapy.
Xu X; Yang Y; Liu X; Cao N; Zhang P; Zhao S; Chen D; Li L; He Y; Dong X; Wang K; Lin H; Mao N; Liu L
Oncologist; 2020 Jun; 25(6):e955-e963. PubMed ID: 32272498
[TBL] [Abstract][Full Text] [Related]
12. PDL1 high expression without TP53, KEAP1 and EPHA5 mutations could better predict survival for patients with NSCLC receiving atezolizumab.
Wang H; Shan Q; Guo J; Han X; Zhao C; Li H; Wang Z
Lung Cancer; 2021 Jan; 151():76-83. PubMed ID: 33246647
[TBL] [Abstract][Full Text] [Related]
13. Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1 levels.
Sun L; Handorf EA; Zhou Y; Borghaei H; Aggarwal C; Bauman J
Lung Cancer; 2024 Apr; 190():107510. PubMed ID: 38432028
[TBL] [Abstract][Full Text] [Related]
14. Correlation between Programmed Death Ligand-1(PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype.
Pandey RK; Shukla S; Husain N; Islam MH; Hadi R; Kant Tripathi S; Singhal A
Asian Pac J Cancer Prev; 2022 Jan; 23(1):131-142. PubMed ID: 35092381
[TBL] [Abstract][Full Text] [Related]
15. The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy.
Proulx-Rocray F; Routy B; Nassabein R; Belkaid W; Tran-Thanh D; Malo J; Tonneau M; Ouarzadi OE; Florescu M; Tehfe M; Blais N
Cancer Treat Res Commun; 2023; 37():100767. PubMed ID: 37832364
[TBL] [Abstract][Full Text] [Related]
16. Real-world progression-free survival (rwPFS) and the impact of PD-L1 and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy.
Bodor JN; Bauman JR; Handorf EA; Ross EA; Clapper ML; Treat J
J Cancer Res Clin Oncol; 2023 May; 149(5):1755-1763. PubMed ID: 35708776
[TBL] [Abstract][Full Text] [Related]
17. Novel Kras-mutant murine models of non-small cell lung cancer possessing co-occurring oncogenic mutations and increased tumor mutational burden.
Salehi-Rad R; Li R; Tran LM; Lim RJ; Abascal J; Momcilovic M; Park SJ; Ong SL; Shabihkhani M; Huang ZL; Paul M; Shackelford DB; Krysan K; Liu B; Dubinett SM
Cancer Immunol Immunother; 2021 Aug; 70(8):2389-2400. PubMed ID: 33507343
[TBL] [Abstract][Full Text] [Related]
18. The Genomic Landscape of
Schoenfeld AJ; Bandlamudi C; Lavery JA; Montecalvo J; Namakydoust A; Rizvi H; Egger J; Concepcion CP; Paul S; Arcila ME; Daneshbod Y; Chang J; Sauter JL; Beras A; Ladanyi M; Jacks T; Rudin CM; Taylor BS; Donoghue MTA; Heller G; Hellmann MD; Rekhtman N; Riely GJ
Clin Cancer Res; 2020 Nov; 26(21):5701-5708. PubMed ID: 32709715
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
[TBL] [Abstract][Full Text] [Related]
20. STK11/LKB1-Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy and Represents STING/Type I Interferon/CD8
Li A; Wang Y; Yu Z; Tan Z; He L; Fu S; Shi M; Du W; Luo L; Li Z; Liu J; Zhou Y; Fang W; Yang Y; Zhang L; Hong S
J Thorac Oncol; 2023 Dec; 18(12):1714-1730. PubMed ID: 37495171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
